| Literature DB >> 27872612 |
Sadegh Azimzadeh Jamalkandi1, Sayed-Hamidreza Mozhgani2, Hamid Gholami Pourbadie3, Mehdi Mirzaie4, Farshid Noorbakhsh5, Behrouz Vaziri6, Alireza Gholami7, Naser Ansari-Pour8, Mohieddin Jafari9.
Abstract
The prototypical neurotropic virus, rabies, is a member of the Rhabdoviridae family that causes lethal encephalomyelitis. Although there have been a plethora of studies investigating the etiological mechanism of the rabies virus and many precautionary methods have been implemented to avert the disease outbreak over the last century, the disease has surprisingly no definite remedy at its late stages. The psychological symptoms and the underlying etiology, as well as the rare survival rate from rabies encephalitis, has still remained a mystery. We, therefore, undertook a systems biomedicine approach to identify the network of gene products implicated in rabies. This was done by meta-analyzing whole-transcriptome microarray datasets of the CNS infected by strain CVS-11, and integrating them with interactome data using computational and statistical methods. We first determined the differentially expressed genes (DEGs) in each study and horizontally integrated the results at the mRNA and microRNA levels separately. A total of 61 seed genes involved in signal propagation system were obtained by means of unifying mRNA and microRNA detected integrated DEGs. We then reconstructed a refined protein-protein interaction network (PPIN) of infected cells to elucidate the rabies-implicated signal transduction network (RISN). To validate our findings, we confirmed differential expression of randomly selected genes in the network using Real-time PCR. In conclusion, the identification of seed genes and their network neighborhood within the refined PPIN can be useful for demonstrating signaling pathways including interferon circumvent, toward proliferation and survival, and neuropathological clue, explaining the intricate underlying molecular neuropathology of rabies infection and thus rendered a molecular framework for predicting potential drug targets.Entities:
Keywords: microarray; protein–protein interaction network; rabies; real-time PCR; signaling network; systems biology
Year: 2016 PMID: 27872612 PMCID: PMC5098112 DOI: 10.3389/fmicb.2016.01688
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1The abstract flowchart of this study design. (A) The four steps taken to obtain the primitive interaction network of the RABV infection. The first step was a systematic review of the literature regarding the RABV. GEO was used to obtain the expression values of studies at the two levels of expression profiling by array of coding and non-coding RNA. Having selected the studies according to our data integration criteria, we moved on to the second step in which we detected DEGs at each level using non-parametric methods. The third step included integration of results using the meta-analysis techniques described in Ramasamy et al. (2008). The implemented integration method revealed that 166 mRNA and 51 microRNA (9057 microRNA targets) are differentially expressed. The next step consisted of super horizontal integration of all transcriptome data. Finally, the 9162 expressed genes were mapped to STRING v 10.0 for further analysis. (B) The next stage of the approach which comprised three steps resulted in the rabies-implicated signaling network (RISN). Firstly, the PPIN of all 9162 genes was reconstructed using STRING v10. The combined score calculated in STRING was used as edge weight in the SHIDEG-PPIN. In the second step, the proximal nodes of the seed gene set (nodes) in the whole SHIDEG-PPIN were found to create the seed neighborhood network. Module finding was undertaken along with the global network analysis. Next, the significantly enriched signaling pathways were extracted in the network modules separately. These pathways were then merged together, forming the rabies-implicated signaling network (RISN). Finally, analysis the global network and functional module finding analysis was performed followed by biological inference.
Seed gene set.
| Myd88 | Myeloid differentiation primary response 88 | Up | Down | |
| Il7r | Interleukin 7 receptor | Up | Down | |
| Ccnb1 | Cyclin B1 | Up | Down | |
| B4galt1 | UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 | Up | Down | |
| Cmya5 | Cardiomyopathy associated 5 | Down | Up | |
| Amotl1 | Angiomotin like 1 | Down | Up | |
| Styk1 | Serine/Threonine/Tyrosine kinase 1 | Down | Up | |
| HAP1 | Huntingtin-associated protein 1 | Down | Up | |
| Slc16a4 | Solute carrier family 16, member 4 | Down | Up | |
| Cyth4 | Cytohesin 4 | Down | Up | |
| Ctsz | Cathepsin Z | Down | Up | |
| Pnp | Purine nucleoside phosphorylase | Down | Up | |
| Grap2 | GRB2-related adaptor protein 2 | Down | Up | |
| Crem | CAMP responsive element modulator | Down | Up | |
| CXCL10 | Chemokine (C-X-C motif) ligand 10 | Down | Up | |
| Angptl4 | Angiopoietin-like 4 | Down | Up | |
| Baz1a | Bromodomain adjacent to zinc finger domain, 1A | Down | Up | |
| KLRA3 | Killer cell lectin-like receptor 3 | Down | Up | |
| GBP2 | Guanylate binding protein 2, interferon-inducible | Down | Up | |
| Lhx2 | LIM homeobox 2 | Down | Up | |
| Apod | Apolipoprotein D | Down | Up | |
| Arhgap9 | Rho GTPase activating protein 9 | Down | Up | |
| Gas1 | Growth arrest-specific 1 | Down | Up | |
| MITD1 | MIT, microtubule interacting and transport, domain containing 1 | Down | Up | |
| Tom1l1 | Target of myb1 (chicken)-like 1 | Down | Up | |
| Glipr2 | GLI pathogenesis-related 2 | Down | Up | |
| Sh2d1b1 | SH2 domain-containing protein 1B | Down | Up | |
| A630001G21Rik | Protein A630001G21Rik | Down | Up | |
| Ncr1 | Natural cytotoxicity triggering receptor 1 | Down | Up | |
| Saa2 | Serum amyloid A2 | Down | Up | |
| Ing5 | Inhibitor of growth family, member 5 | Down | Up | |
| Laptm5 | Lysosomal protein transmembrane 5 | Down | Up | |
| Kmo | Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) | Down | Up | |
| Dusp2 | Dual specificity phosphatase 2 | Down | Up | |
| Ctla2b | Protein CTLA-2-beta | Down | Up | |
| Cd93 | CD93 molecule | Down | Up | |
| Serpinb1c | Leukocyte elastase inhibitor C | Down | Up | |
| 4930486L24Rik | Testin-2 | Down | Up | |
| USP18 | Ubiquitin specific peptidase 18 | Down | Up | |
| Gosr1 | Golgi SNAP receptor complex member 1 | Down | Up | |
| Tnfaip3 | Tumor necrosis factor, alpha-induced protein 3 | Down | Up | |
| IL15RA | Interleukin 15 receptor, alpha | Down | Up | |
| Eif4ebp1 | Eukaryotic translation initiation factor 4E binding protein 1 | Down | Up | |
| Fbxl5 | F-box and leucine-rich repeat protein 5 | Down | Up | |
| Tnfrsf11a | Tumor necrosis factor receptor superfamily, member 11a, NFKB activator | Down | Down | |
| Ly6c1 | Lymphocyte antigen 6C1 | Down | Down | |
| Il1a | Interleukin 1, alpha | Down | Down | |
| Aida | Axin interactor, dorsalization associated | Down | Down | |
| Mmp19 | Matrix metallopeptidase 19 | Down | Down | |
| Csf1 | Colony stimulating factor 1 (macrophage) | Down | Down | |
| Arrdc4 | Arrestin domain containing 4 | Down | Down | |
| Nampt | Nicotinamide phosphoribosyltransferase | Down | Down | |
| Nfkb2 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | Down | Down | |
| Fkbp5 | FK506 binding protein 5 | Down | Down | |
| Klhl5 | Kelch-like family member 5 | Up | Up | |
| Snx10 | Sorting nexin 10 | Up | Up | |
| SERPINB9 | Serpin peptidase inhibitor, clade B (ovalbumin), member 9 | Up | Up | |
| IGF2 | Insulin-like growth factor 2 | Up | Up | |
| IFI204 | Interferon-activable protein 204 | Up | Up | |
| Il17ra | Interleukin 17 receptor A | Up | Up | |
| Zc3h12a | Zinc finger CCCH-type containing 12A | Up | Up |
The 61 seed genes are presented in this table. The green, red, and yellow color indicate over-, under, and ambivalent expression of genes regarding mRNA and microRNA expression evidence.
Figure 2The significant GO terms based on the seed gene set. The enriched GO terms within (A) biological processes, (B) cellular components, and (C) molecular functions are presented separately. All terms were statistically significant (P < 0.05) and are ranked based on Enrichr combined scores.
Figure 3The network (SHIDEG-PPIN) onion diagram. (A) Identification of the rabies disease neighborhood network based on proximal nodes of the seed gene set. The PPIN of all DEG products (8602/9162) existed in STRING were ranked on the basis of their shortest path (SP) score with the 61 rabies SHIDEGs as seed nodes. Selecting various score cutoffs (99.5th, 95th and 56th quantiles) allow neighborhoods of various sizes to be defined as shown in the nested circles. The ranked list of neighbors of seed nodes demonstrated with their scores. (B) The minimized PPIN formed with the confident interactions (0.4 cut-off selected based on the TOM procedure) between the 61 seed nodes (green) and top 45 ranked proximal nodes (range of colors from cyan to purple) is shown at the top with node size representing degree of nodes.
Figure 4Top ranked nodes based on two centrality measures. The (A) degree and (B) betweenness centrality measures were calculated in the 12 modules (M1–M12) of the SHIDEG-PPIN proximal neighborhood network of the seed gene set. The over-expression and under-expression of these gene products are labeled by color.
The enriched KEGG and Reactome pathways.
| M1 | Vasopressin-regulated water reabsorption | 26 | 1.13E-33 | Peptide ligand-binding receptors | 22 | 9.62E-30 |
| Calcium signaling pathway | 21 | 2.76E-28 | Platelet activation, signaling, and aggregation | 10 | 2.76E-08 | |
| cGMP-PKG signaling pathway | 7 | 2.56E-05 | Thrombin signaling through proteinase activated receptors (PARs) | 7 | 2.49E-10 | |
| M2 | PI3K-Akt signaling pathway | 30 | 2.16E-24 | Immune system | 49 | 9.78E-28 |
| Pathways in cancer | 30 | 1.26E-22 | Innate immune system | 38 | 1.31E-25 | |
| Ras signaling pathway | 29 | 2.10E-28 | Adaptive immune system | 35 | 6.87E-23 | |
| M3 | Cell cycle | 10 | 1.71E-11 | Cell cycle | 28 | 4.52E-31 |
| Vasopressin-regulated water reabsorption | 2 | 2.42E-02 | Cell cycle, mitotic | 27 | 4.64E-31 | |
| Bladder cancer | 2 | 4.17E-02 | M Phase | 12 | 1.80E-10 | |
| M4 | Neuroactive ligand–receptor interaction | 16 | 3.08E-22 | G alpha (s) signaling events | 23 | 1.04E-47 |
| – | – | – | GPCR ligand binding | 21 | 1.91E-29 | |
| – | – | – | Class B/2 (secretin family receptors) | 10 | 5.73E-16 | |
| M5 | Chemokine signaling pathway | 25 | 1.78E-29 | Signaling by GPCR | 68 | 2.40E-78 |
| Neuroactive ligand-receptor interaction | 25 | 2.85E-25 | GPCR downstream signaling | 63 | 2.90E-70 | |
| Cytokine-cytokine receptor interaction | 20 | 4.75E-18 | G alpha (i) signaling events | 63 | 1.24E-110 | |
| M6 | Thyroid hormone signaling pathway | 12 | 1.56E-12 | Generic transcription pathway | 46 | 3.10E-54 |
| Notch signaling pathway | 8 | 8.68E-10 | Developmental biology | 28 | 1.47E-24 | |
| Maturity onset diabetes of the young | 3 | 7.71E-03 | Nuclear receptor transcription pathway | 27 | 4.31E-53 | |
| M7 | Regulation of actin cytoskeleton | 9 | 1.74E-06 | Signaling by Rho GTPases | 52 | 1.49E-77 |
| Pancreatic cancer | 3 | 3.45E-02 | Rho GTPase cycle | 51 | 1.99E-104 | |
| – | – | – | G alpha (12/13) signaling events | 17 | 1.45E-25 | |
| M8 | Ubiquitin mediated proteolysis | 8 | 2.36E-12 | Association of TriC/CCT with target proteins during biosynthesis | 4 | 1.40E-07 |
| Circadian rhythm | 2 | 1.19E-03 | Protein folding | 4 | 1.44E-06 | |
| – | – | – | Chaperonin-mediated protein folding | 4 | 1.04E-06 | |
| M9 | Jak-STAT signaling pathway | 37 | 2.06E-50 | Immune system | 57 | 3.06E-41 |
| Cytokine–cytokine receptor interaction | 36 | 1.80E-39 | Cytokine signaling in immune system | 53 | 1.54E-67 | |
| Measles | 26 | 9.44E-32 | Interferon signaling | 31 | 1.08E-35 | |
| M10 | MAPK signaling pathway | 25 | 3.59E-24 | Innate immune system | 31 | 2.54E-21 |
| Pathways in cancer | 23 | 7.36E-17 | Toll-like receptors cascades | 19 | 1.54E-20 | |
| PI3K-Akt signaling pathway | 22 | 7.01E-17 | Toll like receptor 3 (TLR3) cascade | 18 | 7.97E-22 | |
| M11 | Wnt signaling pathway | 33 | 6.80E-57 | Signaling by Wnt | 30 | 1.06E-37 |
| Pathways in cancer | 28 | 2.05E-31 | TCF dependent signaling in response to WNT | 23 | 1.72E-28 | |
| Melanogenesis | 26 | 2.21E-44 | Class B/2 (secretin family receptors) | 18 | 1.63E-27 | |
| M12 | – | – | – | Amyloids | 5 | 1.21E-09 |
| – | – | – | Disease | 5 | 8.05E-05 |
The statistically significantly enriched KEGG and Reactome pathways were identified by ClueGO. The top three representative pathways identified in each module (M1–M12) of the SHIDEG-PPIN proximal neighborhood network are given together with their corrected p-values. The highlighted pathway names were found to be enriched in more than one module.
Figure 5A bird's eye view of RISN. The 22 over-expressed genes of significantly enriched KEGG pathways were selected and merged. The DEGs are labeled by different colors including orange and blue which indicates down-regulation and up-regulation of genes, respectively. The activator/inhibitor edges are also colored differently (red edges are inhibitors and black vice versa). The node colors represent its relative position in a directed network from brown (source nodes), cream (internal nodes) to green (sink nodes) and the node size is proportional to betweenness centrality value. In addition, the six detected modules in three parts are displayed separately: (A) Interferon circumvent, (B) Toward proliferation and survival, and (C) neuropathological clue.
Details of the main sink and source nodes along with high betweenness centrality values in the whole RISN.
| CCL11 | Chemokine (C-C motif) ligand 11 | Source | Down | |
| CCL20 | Chemokine (C-C motif) ligand 20 | Source | Down | |
| CCL22 | Chemokine (C-C motif) ligand 22 | Source | Up | |
| CCL28 | Chemokine (C-C motif) ligand 28 | Source | Up | |
| CCL3 | Chemokine (C-C motif) ligand 3 | Source | Up | Highly activated in the brains of mice infective with Rabies (71) |
| CCL5 | Chemokine (C-C motif) ligand 5 | Source | Up | Known as a vital regulator which is involved in convincing encephalomyelitis (72), raised levels of mRNA transcripts (73), the expression value of CXCL10 and CCL5 in microglia is accurately regulated while the multiple signaling pathways are activated |
| CD28 | CD28 molecule | Source | Up | |
| CDC37 | Cell division cycle 37 | Source | Up | |
| CNTF | Ciliary neurotrophic factor | Source | Up | |
| CX3CL1 | Chemokine (C-X3-C motif) ligand 1 | Source | Up | |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) | Source | Up | |
| CXCL10 | Chemokine (C-X-C motif) ligand 10 | Source | Up | Known as a vital regulator which is involved in convincing encephalomyelitis (72), raised levels of mRNA transcripts (73), the expression value of CXCL10 and CCL5 in microglia is accurately regulated while the multiple signaling pathways are activated |
| CXCL12 | Chemokine (C-X-C motif) ligand 12 | Source | Up | |
| CXCL16 | Chemokine (C-X-C motif) ligand 16 | Source | Down | |
| CXCL2 | Chemokine (C-X-C motif) ligand 2 | Source | Up | |
| CXCL5 | Chemokine (C-X-C motif) ligand 5 | Source | Up | |
| DLL1 | Delta-like 1 (Drosophila) | Source | Down | |
| HSP90AA1 | Heat shock protein 90 kDa alpha family class A member 1 | Source | Up | Associated with virus packaging (68) |
| HSP90AB1 | Heat shock protein 90 kDa alpha family class B member 1 | Source | Up | Associated with virus packaging (68) |
| HSP90B1 | Heat shock protein 90 kDa beta family member 1 | Source | Up | Associated with virus packaging (68) |
| IL11 | Interleukin 11 | Source | Up | |
| IL3 | Interleukin 3 | Source | Up | |
| JAG1 | Jagged 1 | Source | Up | |
| LPAR1 | Lysophosphatidic acid receptor 1 | Source | Down | |
| LPAR2 | Lysophosphatidic acid receptor 2 | Source | Up | |
| LPAR4 | Lysophosphatidic acid receptor 4 | Source | Down | |
| MAML1 | Mastermind like transcriptional coactivator 1 | Source | Down | |
| MAML2 | Mastermind like transcriptional coactivator 2 | Source | Down | |
| ANGPTL4 | Angiopoietin like 4 | Sink | Down | |
| BCL2L1 | BCL2-like 1 | Sink | Down | |
| IL17F | Interleukin 17F | Sink | Down | |
| MCL1 | Myeloid cell leukemia 1 | Sink | Up | |
| PCK1 | Phosphoenolpyruvate carboxykinase 1 (soluble) | Sink | Up | |
| IL21 | Interleukin 21 | 1.62 | Down | IL-21 is critical for the development of optimal vaccine-induced primary but not secondary antibody responses against RABV infections (Dorfmeier et al., |
| IFNB1 | Interferon, beta 1, fibroblast | 1.19 | Up | RABV P protein binds and inhibit Binding to IRF3 (Brzózka et al., |
| EP300 | E1A binding protein p300 | 0.70 | Down | |
| TLR4 | Toll-like receptor 4 | 0.64 | Down | No sign of phenotype due to lacking TLR4 |
| IL6 | Interleukin 6 | 0.58 | Up | Overexpression during infection (58,59), correlation among the IL-6 genes and the way of behavioral lateralization (60), involved in RABV pathogenesis (61) |
| MYD88 | Myeloid differentiation primary response 88 | 0.44 | Down | Weakened RABV intervenes deadly disease while no MyD88 present, genetic adjuvanting with Myd88 improved the RVNA responses of a plasmid DNA rabies vaccine (90,91) |
| NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | 0.13 | Down | |
| STAT3 | Signal transducer and activator of transcription 3 (acute-phase response factor) | 0.12 | Down | inhibits STAT3 nuclear accumulation (Lieu et al., |
| TRAF6 | TNF receptor associated factor 6 | 0.08 | Up | |
| F2R | Coagulation factor II (thrombin) receptor | 0.05 | Up | |
| CASP8 | Caspase 8, apoptosis-related cysteine peptidase | 0.00 | Up | Activation in RABV (Sarmento et al., |
| GNAI2 | Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 | 0.00 | Down | |
| RBL1 | Retinoblastoma-like 1 | 0.00 | Down | |
| TFDP2 | Transcription factor Dp-2 (E2F dimerization partner 2) | 0.00 | Down | |
| STAT1 | Signal transducer and activator of transcription 1 | −0.01 | Down | RABV P protein binds and inhibit dimerization of STAT (Vidy et al., |
| AKT2 | v-AKT murine thymoma viral oncogene homolog 2 | −0.07 | Up | Hyper-phosphorylation of RABV P protein (Sun et al., |
| AKT3 | v-AKT murine thymoma viral oncogene homolog 3 | −0.07 | Up | Hyper-phosphorylation of RABV P protein (Sun et al., |
| JUN | Jun proto-oncogene | −0.32 | Up | Activated in Rabies (Nakamichi et al., |
| FASLG | Fas ligand (TNF superfamily, member 6) | −0.48 | Up | Immune disruptive strategy of RABV to bring about apoptosis in T cell by overexpression in neuron (93) |
| IRF7 | Interferon regulatory factor 7 | −0.60 | Up | RABV P protein averts tis activation (70) |
| ADCY6 | Adenylate cyclase 6 | −0.70 | Up | The signal pathway from the stimulating regulatory component of the adenylate cyclase system to the unchanged activity of the catalytic subunit is defective (Koschel and Halbach, |
| ADCY1 | Adenylate cyclase 1 (brain) | −0.73 | Down | The signal pathway from the stimulating regulatory component of the adenylate cyclase system to the unchanged activity of the catalytic subunit is defective (Koschel and Halbach, |
| ADCY7 | Adenylate cyclase 7 | −0.73 | Up | The signal pathway from the stimulating regulatory component of the adenylate cyclase system to the unchanged activity of the catalytic subunit is defective (Koschel and Halbach, |
| ADCY9 | Adenylate cyclase 9 | −0.73 | Down | The signal pathway from the stimulating regulatory component of the adenylate cyclase system to the unchanged activity of the catalytic subunit is defective (Koschel and Halbach, |
| IRF3 | Interferon regulatory factor 3 | −0.78 | Up | RABV P protein binds and avert binding to IFNB1 (53), inhibit IRF3 phosphorylation (70,96) |
| JAK2 | Janus kinase 2 | −0.79 | Up |
The third and fourth column indicate the position (Po.) of the corresponding genes in RISN and expression changes (U/D) of them based on our meta-analysis. The IRI of the nodes with high betweenness values are presented in the third column
Figure 6The manually curated version of RISN. The over- and under-expressed genes are colored green and yellow, respectively. The cellular membrane and nuclear membrane are depicted by gray solid and dashed lines, respectively. Proteins are depicted by rounded rectangles, and DNA and small metabolite molecules are shown by circle. The phosphorylated P protein activated by AKT is denoted by P*, however, for the sake of simplicity, its process is not shown in the signaling pathway. Viral components are depicted by red shapes but with different caps to delineate activatory and inhibitory effects of RABV on RISN.
Figure 7Experimental validation of microarray-based expression results. (A) Mock infected N2a cell culture image showing a normal morphology. (B) N2a cells infected with CVS strain of RABV with multiplicity of infection (MOI = 3), stained by FITC conjugated anti-rabies nucleocapsid polycolonal antibody. The images were captured 24 h post infection. (C) Expression profile of three randomly selected genes acting in different signaling pathways of the rabies-implicated signaling network (RISN). Expression levels were quantified using RT-qPCR in triplicates. The error bar plots indicate Mean ± SD and include the corresponding p-value of the statistical significance test. The vertical axis measures the negative inverse value of the logarithm of the mean value for each replicate using the delta Ct method.
Figure 8The manually curated version of RISN in a nutshell. To summarize the biological processes involved in the infected neuron, the signaling pathways along with their triggers and consequences are delineated based on Figure 6. Activated and inhibited pathways are colored green and red, respectively. Viral components are depicted by red shapes but with different caps to delineate activatory and inhibitory effects of RABV on RISN.